Dr Adam Parslow
Honorary (Fellow)
Baker Department of Cardiometabolic Health
14 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
DOI: 10.1158/1535-7163.MCT-24-05832024
Journal article
Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation
DOI: 10.1042/CS202401782024
Journal article
An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy
DOI: 10.3390/cancers161019022021
Journal article
The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile
DOI: 10.1126/sciadv.abf44082021
Journal article
Host il11 signaling suppresses cd4 t cell-mediated antitumor responses to colon cancer in mice
DOI: 10.1158/2326-6066.CIR-19-10232020
Journal article
Synthesis and validation of [18F]mBPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on a benzofuran backbone
DOI: 10.1186/s41181-020-0089-92020
Journal article
New insights into ErbB3 function and therapeutic targeting in cancer
DOI: 10.1080/14737140.2020.1829485
RECENT SCHOLARLY WORKS
2018
Conference Proceedings
Preclinical evaluation of a mTOR specific PET ligand in a RAD001 sensitive/resistant breast cancer model system
2018
Journal article
Confocal microscopy reveals cell surface receptor aggregation through image correlation spectroscopy
DOI: 10.3791/571642018
Conference Proceedings
DEVELOPMENT OF MTORC1 SPECIFIC AGENTS FOR EVALUATION OF HER2 TARGETED THERAPY USING PET